<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669669</url>
  </required_header>
  <id_info>
    <org_study_id>2000.00</org_study_id>
    <secondary_id>NCI-2013-00701</secondary_id>
    <secondary_id>8357</secondary_id>
    <secondary_id>2000.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00669669</nct_id>
  </id_info>
  <brief_title>O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas</brief_title>
  <official_title>Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of temozolomide when given
      together with radiation therapy, carmustine, O6-benzylguanine, and patients' own stem cell
      (autologous) transplant in treating patients with newly diagnosed glioblastoma multiforme or
      gliosarcoma. Giving chemotherapy, such as temozolomide, carmustine, and O6-benzylguanine, and
      radiation therapy before a peripheral stem cell transplant stops the growth of cancer cells
      by stopping them from dividing or killing them. Giving colony-stimulating factors, such as
      filgrastim or plerixafor, and certain chemotherapy drugs, helps stem cells move from the bone
      marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is
      then given to prepare the bone marrow for the stem cell transplant. The stem cells are then
      returned to the patient to replace the blood-forming cells that were destroyed by the
      chemotherapy and radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the safety and feasibility of infusing autologous granulocyte colony-stimulating
      factor (G-CSF) (filgrastim) mobilized stem cells transduced with a Phoenix-gibbon ape
      leukemia virus (GALV)-pseudotype vector expressing methylguanine methyltransferase (MGMT)
      (P140K).

      II. Define the dose of BCNU (carmustine) that results in efficient engraftment of gene
      modified cells when given with peripheral blood stem cell support.

      SECONDARY OBJECTIVES:

      I. Determine the engraftment of gene-modified cells after conditioning with BCNU.

      II. Determine the ability to select gene-modified cells in vivo with this regimen.

      III. Evaluate the molecular and clonal composition of gene-modified cells after chemotherapy
      with temozolomide.

      IV. Observe patients for clinical anti-tumor response.

      V. Determine the correlation of the level of MGMT (P140K) marking with toxicity, temozolomide
      dose achieved, and response.

      VI. Characterize the toxicity associated with this regimen.

      OUTLINE: This is a phase I, dose-escalation study of temozolomide followed by a phase II
      study.

      PART I: Within 35 days of surgery, patients undergo 3 dimensional (3D) conformal
      intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy daily 5 days
      per week for 6 weeks. Patients receive filgrastim subcutaneously (SC) on days -7 to -3 and
      begin stem cell collection on the 4th day of filgrastim administration (up to 3 apheresis).
      Patients may also receive plerixafor SC on days -5 to -3. The CD34+ stem cells are separated
      from the patient's stem cells and they are transduced with Phoenix-RD114 pseudotype vector
      (retrovirus). One day after apheresis is completed, patients receive carmustine intravenously
      (IV) over 3 hours followed 2 hours later by temozolomide orally (PO). At least twenty-four
      hours after completion of carmustine and temozolomide, patients undergo reinfusion of
      genetically-modified stem cells.

      PART II: Beginning approximately 4 weeks after completion of Phase 1 of the study, patients
      receive O6-benzylguanine IV continuously over 48 hours followed by temozolomide PO within 1
      hour. Treatment may repeat at least every 28 days for a total of 24 courses in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 1-3 months for 2 years,
      every 3-6 months for 3 years, and then annually thereafter for 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 25, 2009</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Actual">July 6, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Up to 6 weeks after infusion</time_frame>
    <description>Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Retrovirus or Leukemia</measure>
    <time_frame>Up to 2 years after infusion</time_frame>
    <description>Replication competent retrovirus or diagnosis of leukemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Survived</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>From the first day of treatment until death, assessed up to 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>From the first day of treatment until unequivocal progression is documented, assessed up to 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene Transfer Efficiency and in Vivo Selection</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Assessed by gene marking in peripheral blood and marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chemoprotection</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3D conformal IMRT</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>3-dimensional radiation therapy</other_name>
    <other_name>3D CONFORMAL RADIATION THERAPY</other_name>
    <other_name>3D CRT</other_name>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In Vitro-Treated Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>in vitro-treated PBPC transplantation</other_name>
    <other_name>in vitro-treated peripheral blood progenitor cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo 3D conformal IMRT</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-Benzylguanine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>6-O-BENZYLGUANINE</other_name>
    <other_name>O(6)-Benzylguanine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>AMD 3100</other_name>
    <other_name>JM-3100</other_name>
    <other_name>Mozobil</other_name>
    <other_name>SDZ SID 791</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Radiation Therapy</intervention_name>
    <description>Undergo proton beam radiation therapy</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>CCRG-81045</other_name>
    <other_name>Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-</other_name>
    <other_name>M &amp; B 39831</other_name>
    <other_name>M and B 39831</other_name>
    <other_name>Methazolastone</other_name>
    <other_name>RP-46161</other_name>
    <other_name>SCH 52365</other_name>
    <other_name>Temcad</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>Temomedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with glioblastoma multiforme or gliosarcoma

          -  The patient or legal guardian must be able to comprehend the informed consent form and
             sign prior to patient enrollment

          -  Karnofsky performance status at time of study entry must be &gt;= 70%

          -  Life expectancy of &gt;= 3 months

          -  Patients must agree to undergo repeat clinical neurological examinations and brain
             magnetic resonance imaging (MRI) with appropriate contrast after every other cycle of
             chemotherapy

          -  White blood cell (WBC) &gt; 3000/ul

          -  Absolute neutrophil count (ANC) &gt; 1500/ul

          -  Platelets &gt; 100,000/ul

          -  Hemoglobin &gt; 10 gm/100ml

          -  Total and direct bilirubin &lt; 1.5 times upper limit of laboratory normal

          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate
             transaminase (SGPT) =&lt; 3 times upper limit of laboratory normal

          -  Alkaline phosphatase =&lt; 3 times upper limit of laboratory normal

          -  Blood urea nitrogen (BUN) &lt; 1.5 times upper limit of laboratory normal

          -  Serum creatinine &lt; 1.5 times upper limit of laboratory normal

          -  Left ventricular ejection fraction (LVEF) &gt;= 40%, however, subjects with a LVEF in the
             range of 40-49% should have cardiology clearance prior to intervention

          -  MGMT promoter methylation analysis of surgically resected tumor or tumor biopsy must
             demonstrate an unmethylated or hypomethylated MGMT promoter status

        Exclusion Criteria:

          -  Patients with cardiac insufficiency and a LVEF of &lt; 40%; history of coronary artery
             disease or arrhythmia, which has required or requires ongoing treatment

          -  Patients with active pulmonary infection and/or pulse oximetry &lt; 90% and a corrected
             diffusion capacity of the lung for carbon monoxide (DLCO) &lt; 70% of predicted

          -  Active systemic infection

          -  Patients who are human immunodeficiency virus (HIV) positive

          -  Pregnant or lactating women; a beta-human chorionic gonadotropin (HCG) level will be
             obtained from women of childbearing potential; fertile men and women should use
             effective contraception

          -  Previous chemotherapy for any malignancy including temozolomide, dacarbazine (DTIC) or
             prior nitrosourea

          -  Diabetes mellitus

          -  Bleeding disorder

          -  Methylated or hypermethylated MGMT promoter status within tumor tissue

          -  Medical or psychiatric condition which in the opinion of the protocol chairman would
             compromise the patient's ability to tolerate this protocol

          -  Prior interstitial radiotherapy, stereotactic or gamma knife surgery or implanted
             BCNU-wafers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Peter Kiem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <results_first_submitted>November 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2018</results_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor octahydrochloride</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT00669669/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
          <description>See Detailed Description
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Carmustine: Given IV
Filgrastim: Given SC
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT
Laboratory Biomarker Analysis: Correlative studies
O6-Benzylguanine: Given IV
Plerixafor: Given SC
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy
Temozolomide: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>To late to start treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
          <description>See Detailed Description
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Carmustine: Given IV
Filgrastim: Given SC
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT
Laboratory Biomarker Analysis: Correlative studies
O6-Benzylguanine: Given IV
Plerixafor: Given SC
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy
Temozolomide: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Dose-limiting Toxicity (DLT)</title>
        <description>Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)</description>
        <time_frame>Up to 6 weeks after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
            <description>See Detailed Description
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Carmustine: Given IV
Filgrastim: Given SC
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT
Laboratory Biomarker Analysis: Correlative studies
O6-Benzylguanine: Given IV
Plerixafor: Given SC
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy
Temozolomide: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Dose-limiting Toxicity (DLT)</title>
          <description>Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Retrovirus or Leukemia</title>
        <description>Replication competent retrovirus or diagnosis of leukemia</description>
        <time_frame>Up to 2 years after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
            <description>See Detailed Description
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Carmustine: Given IV
Filgrastim: Given SC
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT
Laboratory Biomarker Analysis: Correlative studies
O6-Benzylguanine: Given IV
Plerixafor: Given SC
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy
Temozolomide: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Retrovirus or Leukemia</title>
          <description>Replication competent retrovirus or diagnosis of leukemia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Proportion of patients with reduction in tumor burden of a predefined amount</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 15 years</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Survived</title>
        <description>From the first day of treatment until death, assessed up to 15 years</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>From the first day of treatment until unequivocal progression is documented, assessed up to 15 years</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gene Transfer Efficiency and in Vivo Selection</title>
        <description>Assessed by gene marking in peripheral blood and marrow</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chemoprotection</title>
        <description>assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events are collected until through study completion on average 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
          <description>See Detailed Description
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Carmustine: Given IV
Filgrastim: Given SC
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT
Laboratory Biomarker Analysis: Correlative studies
O6-Benzylguanine: Given IV
Plerixafor: Given SC
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy
Temozolomide: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Heme &amp; Lymphatics</sub_title>
                <counts group_id="E1" events="162" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>HEENT</sub_title>
                <counts group_id="E1" events="57" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic &amp; Nutritional</sub_title>
                <counts group_id="E1" events="155" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous</sub_title>
                <counts group_id="E1" events="43" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin &amp; Appendages</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials.Gov FHCRC Office</name_or_title>
      <organization>Fred Hutch Cancer Research Center</organization>
      <phone>2066674520</phone>
      <email>ct.gov@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

